The Efficacy and Safety of Pemafibrate in Patients with Type 2 Diabetes and Elevated Triglyceride levels: 52-Week Data From The PROVIDE Study

Supplementary Appendix
Methods
Study endpoints and statistical analyses
The primary efficacy and safety endpoints were the percentage change in fasting serum triglyceride levels and the incidence of AEs and ADRs, respectively. One-sample t-test or Wilcoxon signed-rank test was used for the differences from the baseline at each time point without multiplicity adjustment. The efficacy and safety of pemafibrate with or without concomitant statin therapy were also evaluated at week 24 and compared with those in the placebo group with post-hoc analyses. In each group, one-sample t-test was used to determine the differences from baseline, and analysis of covariance (ANCOVA) with the baseline as a covariate was used to determine the differences between the placebo group and the pemafibrate groups. The incidence of adverse events was analyzed and compared between the pemafibrate groups and the placebo group using Fisher's exact test in subgroups with or without concomitant statin treatment. Additionally, other post-hoc analyses were performed to discuss this study and compared the results with those of similar long-term clinical trials.
For the analyses of subgroups with and without concomitant statin therapy, one patient in the placebo/pemafibrate 0.2 mg/day group who started statin therapy from week 8 was analyzed as of the subgroup with statin therapy although the patient was not included in those on statin treatment in the patients' characteristics.
